MX2009003750A - Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular. - Google Patents

Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.

Info

Publication number
MX2009003750A
MX2009003750A MX2009003750A MX2009003750A MX2009003750A MX 2009003750 A MX2009003750 A MX 2009003750A MX 2009003750 A MX2009003750 A MX 2009003750A MX 2009003750 A MX2009003750 A MX 2009003750A MX 2009003750 A MX2009003750 A MX 2009003750A
Authority
MX
Mexico
Prior art keywords
intraocular pressure
a3ar
antagonist
adenosine
species
Prior art date
Application number
MX2009003750A
Other languages
English (en)
Spanish (es)
Inventor
Marcel Y Avila
Richard Stone
Civan M Mortimer
Kenneth A Jacobson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2009003750A publication Critical patent/MX2009003750A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
MX2009003750A 2006-10-06 2007-10-05 Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular. MX2009003750A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85017506P 2006-10-06 2006-10-06
PCT/US2007/021409 WO2008045330A2 (en) 2006-10-06 2007-10-05 Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure

Publications (1)

Publication Number Publication Date
MX2009003750A true MX2009003750A (es) 2009-06-18

Family

ID=39283379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003750A MX2009003750A (es) 2006-10-06 2007-10-05 Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.

Country Status (8)

Country Link
US (1) US20090258836A1 (cg-RX-API-DMAC7.html)
EP (1) EP2076267A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010505848A (cg-RX-API-DMAC7.html)
AU (1) AU2007307157A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0715318A2 (cg-RX-API-DMAC7.html)
CA (1) CA2665616A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009003750A (cg-RX-API-DMAC7.html)
WO (1) WO2008045330A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516495A (ja) 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
JP2013523739A (ja) * 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
SMT201700377T1 (it) 2012-01-26 2017-09-07 Inotek Pharmaceuticals Corp Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
US10196396B2 (en) 2016-01-14 2019-02-05 Handok Inc. Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
KR101805400B1 (ko) * 2017-03-21 2017-12-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물
CN109666053A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 一种a3腺苷受体激动剂及其用途
KR102007640B1 (ko) * 2017-11-29 2019-08-07 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 망막 질환 또는 시신경 질환 예방 및 치료용 약학적 조성물
US11395597B2 (en) * 2018-06-26 2022-07-26 General Electric Company System and method for evaluating blood flow in a vessel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4431638B2 (ja) * 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
EP1096975B1 (en) * 1998-07-16 2005-03-16 The Trustees Of The University Of Pennsylvania Use of a3 adenosine receptor antagonists in the manufacture of a medicament for reducing intraocular pressure
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Also Published As

Publication number Publication date
BRPI0715318A2 (pt) 2013-07-16
EP2076267A4 (en) 2013-07-31
US20090258836A1 (en) 2009-10-15
AU2007307157A1 (en) 2008-04-17
WO2008045330A2 (en) 2008-04-17
JP2010505848A (ja) 2010-02-25
EP2076267A2 (en) 2009-07-08
WO2008045330A3 (en) 2008-06-26
CA2665616A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
WO2008045330A3 (en) Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure
MY208749A (en) Biligand drug conjugates and uses thereof
EP2524693B1 (en) Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
EP2533785B1 (en) Treatment of loss of sense of touch with saxitoxin derivatives
IL172082A0 (en) Foamable pharmaceutical compositions and methods for treating a disorder
JP2009501797A5 (cg-RX-API-DMAC7.html)
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
JP6466504B2 (ja) 長時間の眼圧低下効果を有するアルファ−2アドレナリンアゴニスト
EA024042B1 (ru) Способ снижения внутриглазного давления у людей
JP2010505848A5 (cg-RX-API-DMAC7.html)
AU2014232881A1 (en) Neosaxitoxin combination formulations for prolonged local anesthesia
WO2000012098A1 (en) Medicinal compositions for treating eye diseases
BR112018014467A2 (en) drug-antibody synergism technology for disease treatment
WO2009022897A3 (es) Composición farmacéutica sinergica, útil para inhibir la neovascularización (angiogénesis) corneal y retinal y de otros órganos en un humano o animal
EP2671589A1 (en) Medicinal agent for prevention or treatment of diseases associated with intraocular neovascularization and/or intraocular vascular hyperpermeability
CN108261390A (zh) 一种布林佐胺溴莫尼定滴眼液及其制备方法
NO20092764L (no) Isosorbid mononitrat derivater for behandling av okular hypertensjon
US20170368072A1 (en) Par-4 agonists for the treatment of cancer
EP1297849B1 (en) Remedial agent for optic nerve diseases
WO2007075720A8 (en) Topical mecamylamine formulations for ocular administration and uses thereof
JP2009519962A5 (cg-RX-API-DMAC7.html)
EP1410808A1 (en) Optic nerve protecting agents containing alpha 1 receptor blocker as the active ingredient
KR20120112162A (ko) 황반변성 예방 또는 치료용 약학 조성물
US20110281813A1 (en) Method of treating c-kit positive relapsed acute myeloid leukemia

Legal Events

Date Code Title Description
FG Grant or registration